
COMBI-APlus | CDRB436F2410
NCT03551626
JCP051
Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes (COMBI-APlus)
Status:
Closed to Accrual

IIIb
Phase

Adjuvant
Line of Therapy

Prevention
Disease Stage

Biomarker(s)
BRAF V600
Investigational
Product
Bruton's tyrosine kinase (Btk) inhibitor
Treatment Arms
o Experimental: Dabrafenib and trametinib combination therapy